Initial therapy for chronic myelogenous leukemia: playing the odds.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Journal of Clinical Oncology

• Publication date

  1998-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.1998.16.9.2897PMID 9738555
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Population-based age- and sex-specific incidence rates in the 4 main types of leukaemia.

  2009cited by this paper
• A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group.

  1998cited by this paper
• Conversion of interferon-induced, long-term cytogenetic remissions in chronic myelogenous leukemia to polymerase chain reaction negativity.

  1998cited by this paper
• Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia. The German CML Study Group.

  1998cited by this paper
• Association between pretransplant interferon-alpha and outcome after unrelated donor marrow transplantation for chronic myelogenous leukemia in chronic phase.

  1998cited by this paper
• Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia.

  1998cited by this paper
• Early treatment decisions with interferon-alfa therapy in early chronic-phase chronic myelogenous leukemia.

  1998cited by this paper
• Comparative analysis of the impact of risk profile and of drug therapy on survival in CML using Sokal's index and a new score

  1997cited by this paper
• Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group.

  1997cited by this paper
• Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials: Chronic Myeloid Leukemia Trialists' Collaborative Group.

  1997cited by this paper
• Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation

  1997cited by this paper
• Unrelated donor bone marrow transplantation for chronic myelogenous leukemia: a decision analysis.

  1997cited by this paper
• Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16‐year period

  1997cited by this paper
• Chronic myelogenous leukemia in blast crisis: retrospective analysis of prognostic factors in 90 patients

  1996cited by this paper
• Allogeneic bone marrow transplantation for chronic myeloid leukemia. Working Party Chronic Leukemia of the European Group for Blood and Marrow Transplantation (EBMT).

  1996cited by this paper
• Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry.

  1996cited by this paper
• Significance of cytogenetic clonal evolution in chronic myelogenous leukemia.

  1996cited by this paper
• Analysis and validation of prognostic factors for CML. German CML Study Group.

  1996cited by this paper
• Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation.

  1996cited by this paper
• Interferon-alpha and hydroxyurea in early chronic myeloid leukemia: a comparative analysis of the Italian and German chronic myeloid leukemia trials with interferon-alpha.

  1996cited by this paper
• Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction.

  1996cited by this paper
• Treatment of myelogenous leukemia: current status and investigational options.

  1996cited by this paper
• Marrow transplantation for CML: the Seattle experience.

  1996cited by this paper
• Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression.

  1995cited by this paper
• A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase.

  1995cited by this paper
• Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients.

  1995cited by this paper
• Prolonged administration of interferon-alpha in patients with chronic-phase Philadelphia chromosome-positive chronic myelogenous leukemia before allogeneic bone marrow transplantation may adversely affect transplant outcome.

  1995cited by this paper
• Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service.

  1995cited by this paper
• Variable numbers of BCR‐ABL transcripts persist in CML patients who achieve complete cytogenetic remission with interferon‐α

  1995cited by this paper
• UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia.

  1995cited by this paper
• Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group.

  1994cited by this paper
• Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia.

  1994cited by this paper
• Marrow transplantation for patients in accelerated phase of chronic myeloid leukemia.

  1994cited by this paper
• Allogeneic Bone Marrow Transplantation for Chronic Myeloid Leukemia Using Sibling and Volunteer Unrelated Donors: A Comparison of Complications in the First 2 Years

  1993cited by this paper
• Interferon alfa has become a standard in the treatment of chronic myelogenous leukemia.

  1993cited by this paper
• Unrelated donor marrow transplantation therapy for chronic myelogenous leukemia: initial experience of the National Marrow Donor Program.

  1993cited by this paper
• Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase.

  1993cited by this paper
• Bone marrow transplantation for chronic myeloid leukemia: long-term results. Chronic Leukemia Working Party of the European Group for Bone Marrow Transplantation.

  1993cited by this paper
• Treatment of chronic myeloid leukemia by marrow transplantation.

  1993cited by this paper
• Effect of prior interferon alfa therapy on the outcome of allogeneic bone marrow transplantation for chronic myelogenous leukemia.

  1993cited by this paper
• Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program.

  1993cited by this paper
• Treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation after preparation with BuCy2.

  1992cited by this paper
• Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients.

  1991cited by this paper
• PROBABILITY OF FINDING HLA‐MATCHED UNRELATED MARROW DONORS

  1988cited by this paper
• HLA-identical marrow transplantation during accelerated-phase chronic myelogenous leukemia: analysis of survival and remission duration.

  1988cited by this paper
• Marrow transplantation for the treatment of chronic myelogenous leukemia.

  1986cited by this paper
• Cancer incidence and survival in patients 65 years of age and older

  1986cited by this paper
• Chronic myelogenous leukemia: a multivariate analysis of the associations of patient characteristics and therapy with survival.

  1985cited by this paper
• Prognostic discrimination among younger patients with chronic granulocytic leukemia: relevance to bone marrow transplantation.

  1985cited by this paper
• Prognostic discrimination in "good-risk" chronic granulocytic leukemia.

  1984cited by this paper
• Characteristics of the terminal phase of chronic granulocytic leukemia.

  1968cited by this paper

• Treating Philadelphia chromosome/BCR‐ABL1 positive patients with Glivec (Imatinib mesylate): 10 years’ experience at Patan Hospital, Nepal

  2017influential citation
• Racial Differences in Survival of Elderly Adults with Chronic Myeloid Leukemia Before and After the Introduction of Imatinib in the United States

  2016cites this paper
• Disease-related mortality exceeds treatment-related mortality in patients with chronic myeloid leukemia on second-line or later therapy.

  2016cites this paper
• Wrist Accelerometry in the Health, Functional, and Social Assessment of Older Adults

  2016cites this paper
• Retrospective Study of Allogeneic Hematopoietic Stem Cell Transplantation in Philadelphia Chromosome-Positive Leukemia: 25 Years' Experience at Gustave Roussy Cancer Campus.

  2015cites this paper
• Chronic myelogenous leukemia.

  2009cites this paper
• Age at the Time of Presentation in Chronic Myeloid Leukemia Patients Referred to Pakistan Institute of Medical Sciences, Islamabad

  2008cites this paper
• Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia

  2007cites this paper
• Allogeneic hematopoietic progenitor cell transplantation for the treatment of chronic myelogenous leukemia in the era of tyrosine kinase inhibitors: lessons learned to date.

  2007cites this paper
• The Myeloproliferative Syndromes

  2007cites this paper
• DESENVOLVIMENTO DE ENSAIO QUIMILUMINESCENTE BASEADO NA DETERMINAÇÃO DE FOSFATASE ALCALINA PARA DIAGNÓSTICO DIFERENCIAL ENTRE LEUCEMIA MIELÓIDE CRÔNICA E REAÇÕES

  2006cites this paper
• Inhibitors of DNA methylation: beyond myelodysplastic syndromes

  2005cites this paper
• Proteomic analysis of nuclear matrix proteins during arsenic trioxide induced apoptosis in leukemia K562 cells.

  2005cites this paper
• Treatment Patterns, Outcomes and Costs Among Elderly Patients with Chronic Myeloid Leukaemia

  2004cites this paper
• Correlation of Major Cytogenetic Response with a Pharmacogenetic Marker in Chronic Myeloid Leukemia Patients Treated with Imatinib (STI571)

  2004cites this paper
• Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia

  2004cites this paper
• Chronic Myeloid Leukaemia (CMLM, So): An overview and advancement in the treatment

  2003cites this paper
• Hematopoietic cell transplantation in the treatment of leukemia.

  2003cites this paper
• Sudden onset of the blastic phase of chronic myelogenous leukemia

  2003cites this paper
• Chronic myelogenous leukemia: A review and update of therapeutic strategies

  2003cites this paper
• ALLOGENEIC PERIPHERAL BLOOD AND BONE MARROW STEM CELL TRANSPLANTATION FOR CHRONIC MYELOGENOUS LEUKEMIA: A SINGLE CENTER STUDY

  2003cites this paper
• Allogeneic peripheral blood and bone marrow stem cell transplantation for chronic myelogenous leukemia: single center study from Iran.

  2003cites this paper
• TREATMENT, AND NURSING CARE OF PATIENTS WITH

  2003cites this paper
• Hematopoietic transplantation from adult unrelated donors

  2003cites this paper
• Diagnosis, treatment, and nursing care of patients with chronic leukemia.

  2003cites this paper
• Chronic myelogenous leukemia.

  2002cites this paper
• Targeted chemotherapy: chronic myelogenous leukemia as a model

  2002cites this paper
• Trends in transplantation of hematopoietic stem cells from unrelated donors.

  2001cites this paper
• Chronic myelogenous leukemia.

  2001cites this paper
• Chronic myelogenous leukemia in chronic phase

  2001cites this paper
• Implementation of an expert system to determine eligibility and priorities for bone marrow transplants.

  2001cites this paper
• Effect of short-term interferon therapy on the outcome of subsequent HLA-identical sibling bone marrow transplantation for chronic myelogenous leukemia: an analysis from the international bone marrow transplant registry.

  2000influential citation
• Improving availability and safety of unrelated donor transplants

  2000cites this paper
• The influence of early transplantation, age, GVHD prevention regimen, and other factors on outcome of allogeneic transplantation for CML following BuCy

  2000cites this paper
• Therapeutic choices in younger patients with chronic myelogenous leukemia

  2000cites this paper
• Risk factors for severe neuropsychiatric toxicity in patients receiving interferon alfa-2b and low-dose cytarabine for chronic myelogenous leukemia: analysis of Cancer and Leukemia Group B 9013.

  2000cites this paper
• CHRONIC MYELOGENOUS LEUKAEMIA

  2000influential citation
• The Cross-Species Antiviral Activities of Different IFN-tau Subtypes on Bovine, Murine, and Human Cells: Contradictory Evidence for Therapeutic Potential

  1999cites this paper
• Allogeneic hematopoietic stem cell transplantation: current issues and future prospects.

  1999cites this paper
• A prisoner with chronic myeloid leukemia

  1999cites this paper
• Delphi-panel analysis of appropriateness of high-dose therapy and bone marrow transplants in chronic myelogenous leukemia in chronic phase.

  1999cites this paper